Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-16T05:23:36.940Z Has data issue: false hasContentIssue false

Therapeutic effect of risperidona inyetable of long evolution in teenagers

Published online by Cambridge University Press:  16 April 2020

D. López Marco
Affiliation:
Unit Mental Health Infanto Juvenil, Center of Mental Health Cartagena, Murcia, Spain
R. Consuegra Sánchez
Affiliation:
Unit Mental Health Infanto Juvenil, Center of Mental Health Cartagena, Murcia, Spain
I. Mártinez Pérez
Affiliation:
Unit Mental Health Infanto Juvenil, Center of Mental Health Cartagena, Murcia, Spain
A. Gómez Poveda
Affiliation:
Unit Mental Health Infanto Juvenil, Center of Mental Health Cartagena, Murcia, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The pharmacological treatment with oral Risperidona is used for years in infanto-juvenile psychiatry. In many occasions difficulty exists for the fulfillment; well for the appearance of adverse effects or for rejection to the capture or for difficulty of familiar fulfillment.

Aims

To expose from the clinical and welfare expectation, the experience with injectable Risperidona of long duration with three cases clinical whose principal diagnosis is of Mental Delay Moderated with alteration of the associate behavior.

Material and methods

I marry 1: 14-year-old Teenager of age attended in our CSM for Mental Delay and Disorder of conduct to familiar and school level.

CI = 50. It has received diverse antipsychotic and stabilizing treatments of oral form being the discontinuous capture. For one year in treatment with injectable Risperidona 50 mgr/14 days, answering favorably to the treatment, diminishing the conducts heteroagresivas that he was presenting to the beginning.

I marry 2: 15-year-old Teenager of age late Mental and disorder of the disturbing behavior with episodes d excitation, irritability and loss of control.

Not clinical stabilization with oral treatment for lack of familiar adherence. We introduce injectable Risperidona, 7,5 mgr/14 days, pupil to the family to mint of the importance of the treatment and the facility of administration. It improved the adherence to the center and therefore, clinical improvement.

I marry 3: Preadolescente and 13 years and age with compatible symptoms late Mental Moderates do and autistic features with important estereotipias and autoaggressions. For a few months in treatment with Risperidona inyecable 37,5 mgr/14 days with clinical improvement.

Type
P01-319
Copyright
Copyright © European Psychiatric Association2011
Submit a response

Comments

No Comments have been published for this article.